

For patients with ADPKD

When ordering a TKV, either ask for

**maximal bilateral
kidney dimensions**

or

**a calculated total
kidney volume**

Why TKV is important:

In patients with ADPKD, kidney growth and damage often occur before kidney function declines.^{1,2} Height-adjusted TKV (htTKV), calculated using a patient's height and total kidney volume, can be used to determine a patient's ADPKD imaging classification and help identify a patient's risk of ADPKD progression and appropriateness for treatment.^{3,4}

ADPKD=autosomal dominant polycystic kidney disease;
TKV=total kidney volume.



Otsuka America Pharmaceutical, Inc.


When you receive your radiology report:



If you receive maximal bilateral kidney dimensions, electronically calculate TKV and htTKV using the QxMD calculator. Scan the QR code or visit QxMD.com

L=length; W=width; D=depth.
Units for kidney dimensions are in mm.
To get kidney volume in mL, multiply by 0.001.
TKV in mL and height in m for a htTKV in mL/m.

Once you calculate htTKV, plot on the Mayo Imaging Classification tool to determine the risk of progression^{5,6}



Republished with permission of The American Society of Nephrology, from Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. *J Am Soc Nephrol*. 2015;26(1):160-172.

eGFR=estimated glomerular filtration rate.

References: 1. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. *Clin J Am Soc Nephrol*. 2006;1(1):148-157. 2. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. *Nat Rev Nephrol*. 2011;7(10):556-566. 3. Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. *Clin J Am Soc Nephrol*. 2012;7(3):479-486. 4. Yu ASL, Shen C, Landsittel DP, et al. Baseline total kidney volume and the rate of kidney growth are associated with chronic disease progression in autosomal dominant polycystic kidney disease. *Kidney Int*. 2018;93(3):691-699. 5. Magistroni R, Corsi C, Martí T, Torra R. A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease progression. *Am J Nephrol*. 2018;48:67-78. 6. Irazabal MV, Rangel LJ, Bergstrahl EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. *J Am Soc Nephrol*. 2015;26(1):160-172.



Otsuka America Pharmaceutical, Inc.

©2023 Otsuka America Pharmaceutical, Inc. All rights reserved. November 2023 10US23EUP0096